Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364806 | 1.00 | NQO2 (0.44) | NQO2KDM4EGAAABL1PKM | |
| SCHEMBL31472920 | 0.85 | NQO2 (0.43) | NQO2KDM4EGAAABL1PKM | |
| SCHEMBL31472896 | 0.85 | NQO2 (0.43) | NQO2KDM4EGAAABL1PKM | |
| SCHEMBL1710208 | 0.82 | KDM4E (0.44) | NQO2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL12380495 | 0.82 | KDM4E (0.44) | KDM4EGAAALDH1A1HPGDKMT2A | |
| SCHEMBL14967236 | 0.82 | KDM4E (0.51) | KDM4EGAAPKMALDH1A1HPGD | |
| SCHEMBL26042118 | 0.80 | KMT2A (0.44) | NQO2KDM4EPKMALDH1A1HPGD | |
| SCHEMBL24070302 | 0.79 | KDM4E (0.42) | NQO2KDM4EGAAALDH1A1HPGD | |
| SCHEMBL31555817 | 0.79 | SCN10A (0.43) | ALDH1A1HPGDADCY10 | |
| SCHEMBL15525960 | 0.78 | ALDH1A1 (0.44) | KDM4EGAAPKMALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119510615-A | Detection method for specific impurities in Enalastat S1 intermediate | 扬州市普林斯医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025012643-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024067675-A1 | FUSED RING KIF18A INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024042361-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024041573-A1 | FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-2455381-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | Japan Tobacco, Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | NQO2 326/4885KDM4E 931/4885GAA 254/4885 |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | NQO2 358/4885KDM4E 3020/4885GAA 3054/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | NQO2 2145/4885KDM4E 4404/4885GAA 477/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | NQO2 1557/4885KDM4E 459/4885GAA 4020/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | NQO2 3385/4885KDM4E 2993/4885GAA 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.